centro de Prensa
Bienvenido al centro de prensa. Aquí podrás echar un vistazo a las historias, tendencias y desarrollos de investigación y desarrollo que dan forma a las diversas áreas en las que trabajan nuestros clientes y socios.
Micronbrane Medical Team attended ASM Microbe Exhibition in Washington
17 June 2022
Micronbrane Medical Team attended ASM Microbe Exhibition which was held on June 9-13, 2022 in Washington. ASM Microbe counts over 30,000 members worldwide and hosts one of the largest gatherings of microbiologists in the world, with hundreds of industry companies and experts, include 200 cutting-edge sessions. During the conference Micronbrane Team held discussions with major US clinic's reps concerning potential collaborations and looking forward to setting up partnerships in near future.
10 June 2022
Optimizing sequencing costs in metagenomics is crucial in precision medicine today like never before. How to reduce costs of pathogen detection in clinical microbiology? Read the newest White Paper about mitigating sequencing cost with novel technology PaRTI-Seq™
Micronbrane presented with pitch deck at InnoVex 2022
26 May 2022
Micronbrane Medical was selected to present its products and technology at InnoVex 2022 in category of innovative startups. Innovex is one of the biggest event in Pacific Asia and attracts over 18 thousands of visitors each year from 25+ countries. At InnoVex you can see the latest advances and innovations from all other the globe. More than 400 startups join the Event each year to show the technologies that will change our life in future.
Micronbrane was selected by SOSA for IP2 Scaleout Program in USA!
10 May 2022
We are happy to announce that Micronbrane Medical was selected by SOSA for IP2 Scaleout Program in USA. IP2 Scaleout Program is 14 months intensive accelerator program for CEO & founders that are eager to launch, grow and scale their businesses of innovative products and technologies on the global markets. Micronbrane Medical thanks SOSA and i2i for support and trust.
Access Poster of Micronbrane and many other materials from ECCMID 2022 now
4 May 2022
Access poster and online video presentation of Micronbrane Medical and materials of other participants of ECCMID 2022 in the Online Library of ESCMID!
Micronbrane was chosen to join Taiwan Team to represent Taiwan at SelectUSA 2022
4 May 2022
We are happy to announce that Micronbrane Medical was chosen to join and present Taiwan at SelectUSA 2022 Event!
Micronbrane Medical is Presenting in Poster Session at EECMID 2022 in Lisbon Portugal
25 April 2022
We are happy to announce that Micronbrane Medical was chosen to present poster in Poster Session at EECMID 2022 in Lisbon Portugal in the section "Microbiome studies, clinical and diagnostic studies and One Health aspects"
Differential lysis depletion methods – drawbacks, shortcomings and alternatives
29 March 2022
Current diagnosis and research protocols use lysis depletion to avoid host DNA interference and further detect the pathogen involved in infectious diseases. But are all lysis depletion methods just as efficient in reducing host DNA and preserving the microbial community intact? Let's find out how most host DNA depletion methods work compared to the newly developed ones.
How ZISC technology improves leukodepletion
22 March 2022
Biofouling resistance of PP membranes is significantly improved with surface zwitterionization for leukocyte reduction filters. Micronbrane enhanced this technique and developed zwitterionic interface ultra-self-assemble coating technology (global patent) used in Devin filter. The developed membrane can remove more than 95% of nucleated cells from whole blood samples within just 5 minutes. Let's see how it works.
Biochemical and Genetic Basis of Antimicrobial Resistance
14 March 2022
Many threatening pathogens are now resistant to multiple classes of antimicrobial agents. A study tested 500 Streptomyces strains isolated from soil against 21 antibiotics of different class found that all the strains were multidrug resistant to at least 7 of the tested antibiotics (D’Costa et al., 2006). These multidrug-resistant (MDR) organisms cause infections that may compromise effective therapy and limit treatment options.